Inotiv (NASDAQ:NOTV) and CDT Equity (NASDAQ:CDT) Head to Head Comparison
by Tristan Rich · The Markets DailyInotiv (NASDAQ:NOTV – Get Free Report) and CDT Equity (NASDAQ:CDT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.
Risk & Volatility
Inotiv has a beta of 3.77, meaning that its share price is 277% more volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.
Earnings & Valuation
This table compares Inotiv and CDT Equity”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inotiv | $507.36 million | 0.00 | -$68.62 million | ($2.53) | 0.00 |
| CDT Equity | N/A | N/A | -$39.22 million | ($66,338.55) | 0.00 |
CDT Equity has lower revenue, but higher earnings than Inotiv. Inotiv is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Inotiv and CDT Equity, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inotiv | 1 | 0 | 1 | 0 | 2.00 |
| CDT Equity | 1 | 0 | 0 | 0 | 1.00 |
Inotiv presently has a consensus price target of $1.50, suggesting a potential upside of 12,400.00%. Given Inotiv’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Inotiv is more favorable than CDT Equity.
Institutional & Insider Ownership
18.2% of Inotiv shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 7.8% of Inotiv shares are held by insiders. Comparatively, 10.8% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Inotiv and CDT Equity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inotiv | -17.14% | -56.77% | -8.91% |
| CDT Equity | N/A | -4,263.33% | -529.91% |
Summary
Inotiv beats CDT Equity on 9 of the 13 factors compared between the two stocks.
About Inotiv
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
About CDT Equity
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.